ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2674

Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates for Susceptibility to Sjögren’s Syndrome

He Li1, John A. Ice2, Jennifer A. Kelly3, Indra Adrianto2, Stuart B. Glenn4, Kimberly S. Hefner5, Evan G. Vista6, Donald U. Stone7, Raj Gopalakrishnan8, Glen D. Houston9, David M. Lewis10, Michael Rohrer8, Pamela Hughes8, John B. Harley11, Courtney G. Montgomery2, James Chodosh7, James A. Lessard12, Juan-Manuel Anaya13, Barbara M. Segal14, Nelson L. Rhodus15, Lida Radfar16, Mark B. Frank17, R. Hal Scofield18, Christopher J. Lessard19 and Kathy Moser Sivils3, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Hefner Eye Care and Optical Center, Oklahoma City, OK, 6Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, 7Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, 9Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 10College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 11Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 12Valley Bone and Joint Clinic, Grand Forks, ND, 13School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, 14Rheumatology, Hennepin County Medical Center, Minneapolis, MN, 15University of Minnesota, Minneapolis, MN, 16University of Oklahoma Health Sciences Center, Oklahoma City, OK, 17Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 18Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 19Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: genomics and interferons, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjögren's Syndrome I - Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of Europeans. Dysregulation of interferon (IFN)-related pathways is well documented in SS and related autoimmune disorders, like systemic lupus erythematosus. To further characterize the expression of IFN-inducible genes in SS, we performed cis-expression quantitative trait loci (c-eQTL) analysis in SS cases to identify genetic variants regulating proximal IFN-regulated genes.

Methods: We first performed whole blood global gene expression profiling in 162 primary SS cases and 58 healthy controls of European ancestry. In total, 2410 genes were differentially expressed (DE) between SS cases and controls (3.49x10E-22≤q<0.05). Among pathways in which DE genes were identified, pathways involved in type I interferon-mediated signaling (31/70 genes; p=5.56x10E-14) were highly significant. The 31 genes were selected for use as phenotypic traits in c-eQTL analyses in 133 Caucasian SS patients through integration of gene expression data with genotypes from our SS genome-wide association study (GWAS, 424 cases / 2120 controls). Single nucleotide polymorphisms (SNPs) from GWAS data spanning 20kb flanking the target genes were tested for genetic association with expression levels by linear regression using Matrix-eQTL in the R Bioconductor suite.

Results: C-eQTL analysis identified SNPs within and flanking HLA-C (70 SNPs, 3.13x10E-9≤q<0.01) and OAS1 (26 SNPs, 6.29x10E-9≤q<0.01) that are significantly associated with gene expression levels. Alleles of HLA genes are well-documented risk factors for the development of autoimmune disorders, including SS. HLA-C belongs to the highly polymorphic MHC class I heavy chain molecule, and is a major independent genetic determinant of psoriasis and rheumatoid vasculitis. Our GWA study also showed associations of HLA-C eQTL with SS susceptibility with the top p=1.72x10E-22 in rs2844612. The association of rs2844612 with HLA-C expression levels is independent of other non-HLA-C SNPs in the MHC region, such as HLA-DRB1 and HLA-DQB1. Interestingly, the presence of both the risk alleles in HLA-C1 and its receptor killer cell immunoglobulin-like receptor (KIR)-2DS2 (2 extracellular domains with short cytoplasmic domain) is significantly associated with dry eye disease in a Han Chinese population. OAS1, or 2′,5′-oligoadenylate synthetase 1, is a critical component involved in the innate immune response to viral infection through RNA degradation and the inhibition of viral replication. Mutations in OAS1 have been associated with host susceptibility to viral infection. Evidence for association of the OAS1 SNP rs10774671, a splice-site polymorphism associated with multiple sclerosis and type 1 diabetes, increased from p=3.39x10E-3 in our SS GWAS to p=6.29x10E-9 in the c-eQTL analysis. 

Conclusion: Integration of results from genetic studies with gene expression data can help us to interpret downstream functional effects of SS susceptibility loci. These results provide promising novel candidate loci in and around HLA-C and OAS1 for future functional studies to better understand SS pathophysiology.


Disclosure:

H. Li,
None;

J. A. Ice,
None;

J. A. Kelly,
None;

I. Adrianto,
None;

S. B. Glenn,
None;

K. S. Hefner,
None;

E. G. Vista,
None;

D. U. Stone,
None;

R. Gopalakrishnan,
None;

G. D. Houston,
None;

D. M. Lewis,
None;

M. Rohrer,
None;

P. Hughes,
None;

J. B. Harley,
None;

C. G. Montgomery,
None;

J. Chodosh,
None;

J. A. Lessard,
None;

J. M. Anaya,
None;

B. M. Segal,
None;

N. L. Rhodus,
None;

L. Radfar,
None;

M. B. Frank,
None;

R. H. Scofield,
None;

C. J. Lessard,
None;

K. Moser Sivils,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cis-expression-quantitative-trait-loci-analysis-of-dysregulated-interferon-pathway-genes-identifies-hla-c-and-oas1-as-novel-candidates-for-susceptibility-to-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology